US · Healthcare · Biotechnology
EPS came in at -0.11 against a street estimate of -0.14 — a beat of 21.4%.
Analysts rate Gain Therapeutics Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $7.20.
| Fund | Stake |
|---|---|
| Marshall Wace Asset Management Ltd | 4.41% |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 2.61% |
| Potomac Capital Management, Inc. | 2.17% |
| GSA Capital Partners LLP | 1.45% |
| JONES FINANCIAL COMPANIES LLLP | 1.39% |
| Vanguard Capital Management, LLC | 1.10% |
| Geode Capital Management, LLC | 1.04% |
| BlackRock Inc | 0.63% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Gain Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.